Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | ERN1 | O75460 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16056281 | 0.89 | ALOX5AP (0.36) | SSTR5ALDH1A1MAPTCNR1CNR2 | |
| SCHEMBL17535719 | 0.88 | SSTR5 (0.44) | SSTR5ALDH1A1MAPT | |
| SCHEMBL16616530 | 0.88 | SSTR5 (0.35) | SSTR5ERN1ALOX5APFEN1 | |
| SCHEMBL16616396 | 0.84 | ALOX5AP (0.35) | SSTR5ERN1ALOX5APFEN1 | |
| SCHEMBL17535715 | 0.80 | SSTR5 (0.44) | SSTR5ALDH1A1CNR1CNR2SLC6A4 | |
| SCHEMBL17535465 | 0.79 | SSTR5 (0.49) | SSTR5CNR1CNR2ALOX5APFEN1 | |
| SCHEMBL16055896 | 0.78 | SSTR5 (0.38) | SSTR5ALDH1A1MAPT | |
| SCHEMBL16616131 | 0.78 | ALOX5AP (0.33) | ALDH1A1MAPTERN1ALOX5APFEN1 | |
| SCHEMBL17535784 | 0.77 | SSTR5 (0.43) | SSTR5ALDH1A1MAPT | |
| SCHEMBL17535516 | 0.77 | ERN1 (0.33) | ALDH1A1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | SSTR5 1/4885ALDH1A1 2449/4885MAPT 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.